|
|
Commercial Insight: HIV - From the Naïve to the ComplexPublished by: Datamonitor Published: Sep. 2, 2004 - 184 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Objective of the analysis 3 Datamonitor insight into the HIV market 3 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 11 Market definition for this report 11 Current market situation 11 Class overview 13 Nucleoside reverse transcriptase inhibitors 14 Non-nucleoside reverse transcriptase inhibitors 16 Protease inhibitors 17 Entry inhibitors 18 Strategic scoping and focus 19 The emerging markets 21 CHAPTER 3 COUNTRY MARKET ASSESSMENTS 24 Current and future opportunities and threats in the HIV market 24 Global opportunities and threats 24 Opportunities 24 Threats 34 US: opportunities and threats 40 Market overview 40 Opportunities 42 Threats 45 Japan: opportunities and threats 49 Market overview 49 Opportunities 51 Threats 55 France: opportunities and threats 59 Market overview 59 Opportunities 62 Threats 62 Germany: opportunities and threats 64 Market overview 64 Opportunities 66 Threats 67 Italy: opportunities and threats 69 Market overview 69 Opportunities 71 Threats 73 Spain: opportunities and threats 74 Market overview 74 Opportunities 76 Threats 78 UK: opportunities and threats 79 Market overview 79 Opportunities 81 Threats 84 Summary of environmental issues affecting the antiretroviral market size 87 CHAPTER 4 FORECAST ANALYSIS 88 Assumptions and events 88 Events not included 88 Global events 88 Increase in the number of patients receiving antiretroviral therapy 88 Pricing adjustments 89 Product-specific events 90 AHF request for Trizivir to be restricted due to new efficacy data 90 Reyataz labeling expanded to include use with low-dose ritonavir in treatment-experienced patients 90 Launch of new combination drugs - tenofovir/emtricitabine (Truvada) and lamivudine/abacavir (Epzicom) 91 Approval of reformulated versions of Kaletra and Invirase 93 Antiretroviral patent expiries 95 Launch of new drugs with activity against resistant strains of HIV 105 Launch of new entry inhibitors and mABs 108 Country-specific events 111 Increased uptake of Fuzeon in the US 111 Norvir price increase in the US 111 Limitations of data 112 Standard units 112 Japanese market data 112 Regional launch dates for new products 113 Forecasts 113 CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 114 Introduction 114 Case studies 115 Lifecycle management 115 Managing the pill burden 115 Fixed-dose combinations 119 Targeting niche markets 123 Co-infection 123 Antiretroviral use in pregnancy 127 Double-boosting 131 Product positioning 133 Journal advertisements 133 Websites 134 Treatment guidelines 136 APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS 139 Global HIV market data 139 NRTI market data 140 PI market data 151 NNRTI market data 160 Others market data 163 APPENDIX B 164 Journal articles and conference abstracts 164 Press releases 170 General 170 EU 171 France 171 Italy 172 Japan 172 Spain 173 UK 174 US 174 Conferences 177 Websites 178 Organizations 179 Miscellaneous 179 Report methodology 181 About Datamonitor 182 About Datamonitor Healthcare 182 About the Infectious Disease analysis team 183 Disclaimer 184 AbstractIntroductionAs HIV therapy reaches a more mature phase, the antiretroviral market is also entering a new cycle. Companies involved will have to employ new portfolio management strategies to ensure they are optimally positioned to defend against sales erosion. Product positioning and promotional activity will become increasingly important to the successful launch and sales maintenance of new drugs. Scope The HIV market is analyzed in detail on a country basis (including the US, EU5 and Japan), with historic and forecast sales from 1999 to 2014 provided An analysis of key top level opportunities and threats for each of the seven markets is provided A quantification of various key events expected to impact the HIV market and individual drugs is provided, along with a qualitative analysis Various lifecycle management strategies are analyzed, using case studies, and their applicability for the future is determined Highlights Although expected to witness continued growth to 2014, there will be a number of challenges facing those involved in the HIV market, including generic incursion, the launch of new, second generation products and increasing disease complexity. Companies will have to adopt new strategies to maintain their HIV presence in the face of such challenges. Although the US will remain the dominant market, accounting for two thirds of total sales, the Japanese market will experience the fastest growth. Alliances with local companies, taking advantage of their domestic knowledge and presence, will enhance the prospects for benefiting from this growth. Early lifecycle management, such as fixed dose combinations and once-daily reformulation, is recommended to protect against sales erosion from generics and new pipeline products. For some products, establishing a position as the drug of choice in niche markets, such as hepatitis, is a more prudent strategy to ensure maintenance of HIV sales. Reasons to Purchase Understand key drivers in the antiretroviral market and predict the future performance of key compounds Quantify the future size and scope of the HIV market and the potential for new products Evaluate a range of lifecycle-management strategies to combat the threat of generic incursion and quantify the impact of key patent expiries Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||